Continuous Versus Bolus Infusion of Hypertonic Saline in the Treatment of Symptomatic Hyponatremia Caused by SIAD
- PMID: 30882872
- DOI: 10.1210/jc.2019-00044
Continuous Versus Bolus Infusion of Hypertonic Saline in the Treatment of Symptomatic Hyponatremia Caused by SIAD
Abstract
Background: Acute hyponatremia is a medical emergency that confers high mortality, attributed primarily to cerebral edema. Expert guidelines advocate the use of intravenous boluses of hypertonic saline rather than traditional continuous infusion to achieve a faster initial rise in plasma sodium (pNa) concentration. However, there is a limited evidence base for this recommended policy change.
Methods: We prospectively assessed the clinical and biochemical outcomes in patients treated for symptomatic hyponatremia caused by syndrome of inappropriate antidiuresis in response to intravenous bolus treatment with 3% saline (100 mL, repeated up to two more times) and compared the outcomes to retrospective data from patients treated with continuous intravenous infusion of low-dose (20 mL/h) 3% saline.
Results: Twenty-two patients were treated with bolus infusion and 28 with continuous infusion. Three percent saline bolus caused more rapid elevation of pNa at 6 hours [median (range) 6 (2 to11) vs 3 (1 to 4) mmol/L, P < 0.0001], with a concomitant improvement in Glasgow Coma Scale (GCS) [median (range) 3 (1 to 6) vs 1 (-2 to 2), P < 0.0001] at 6 hours. Median pNa concentration was similar at 24 hours in the two treatment groups. The administration of a third saline bolus was associated with greater need for dextrose/dDAVP to prevent overcorrection (OR 24; P = 0.006). There were no cases of osmotic demyelination in either group.
Conclusion: Three percent saline bolus produces faster initial elevation of pNa than continuous infusion with quicker restoration of GCS, and without osmotic demyelination. Frequent electrolyte monitoring, and judicious intervention with dDAVP is required to prevent overcorrection with bolus therapy.
Copyright © 2019 Endocrine Society.
Similar articles
-
Treatment of symptomatic hyponatremia with hypertonic saline: a real-life observational study.Eur J Endocrinol. 2021 May;184(5):647-655. doi: 10.1530/EJE-20-1207. Eur J Endocrinol. 2021. PMID: 33635825 Free PMC article.
-
Efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia: study protocol for a randomized controlled trial (SALSA trial).Trials. 2017 Mar 29;18(1):147. doi: 10.1186/s13063-017-1865-z. Trials. 2017. PMID: 28356136 Free PMC article. Clinical Trial.
-
Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.JAMA Intern Med. 2021 Jan 1;181(1):81-92. doi: 10.1001/jamainternmed.2020.5519. JAMA Intern Med. 2021. PMID: 33104189 Free PMC article. Clinical Trial.
-
Diagnosis and Management of Hyponatremia: A Review.JAMA. 2022 Jul 19;328(3):280-291. doi: 10.1001/jama.2022.11176. JAMA. 2022. PMID: 35852524 Review.
-
Management of severe hyponatremia: infusion of hypertonic saline and desmopressin or infusion of vasopressin inhibitors?Am J Med Sci. 2014 Nov;348(5):432-9. doi: 10.1097/MAJ.0000000000000331. Am J Med Sci. 2014. PMID: 25247759 Free PMC article. Review.
Cited by
-
Syndrome of inappropriate antidiuresis/hyponatremia in COVID-19.Pituitary. 2024 Aug 28. doi: 10.1007/s11102-024-01446-4. Online ahead of print. Pituitary. 2024. PMID: 39196447 Review.
-
Paraneoplastic neurological syndromes of small cell lung cancer.Postep Psychiatr Neurol. 2024 Jun;33(2):80-92. doi: 10.5114/ppn.2024.141157. Epub 2024 Jul 11. Postep Psychiatr Neurol. 2024. PMID: 39119541 Free PMC article. Review.
-
Use of hypertonic saline in severe symptomatic hyponatraemia; results from a national survey of endocrinologists in the United Kingdom.Endocrine. 2024 Dec;86(3):1199-1201. doi: 10.1007/s12020-024-03927-9. Epub 2024 Jun 15. Endocrine. 2024. PMID: 38878192
-
Endocrinologists at work: management of hyponatremia in clinical practice.J Endocrinol Invest. 2023 Dec;46(12):2453-2457. doi: 10.1007/s40618-023-02147-8. Epub 2023 Jul 15. J Endocrinol Invest. 2023. PMID: 37452912 No abstract available.
-
Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.Endocr Oncol. 2022 Jul 11;2(1):R78-R89. doi: 10.1530/EO-22-0056. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435459 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
